EGFR and breast cancer: HER-2/neu is a member of the epidermal growth factor receptor (HER/EGFR/ERBB) family, whose amplification in breast cancer is associated with increased aggressiveness, therefore becoming an important target of therapy for about 20%–30% of patients [68].